Transgene SA

PINK:TRGNF USA Biotechnology
Market Cap
$191.73 Million
Market Cap Rank
#20407 Global
#7411 in USA
Share Price
$0.70
Change (1 day)
+0.00%
52-Week Range
$0.70 - $1.59
All Time High
$4.31
About

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more

Transgene SA (TRGNF) - Total Liabilities

Latest total liabilities as of June 2025: $44.59 Million USD

Based on the latest financial reports, Transgene SA (TRGNF) has total liabilities worth $44.59 Million USD as of June 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Transgene SA - Total Liabilities Trend (1997–2024)

This chart illustrates how Transgene SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Transgene SA Competitors by Total Liabilities

The table below lists competitors of Transgene SA ranked by their total liabilities.

Company Country Total Liabilities
Rugvista Group AB
ST:RUG
Sweden Skr306.50 Million
Rhom Bho Property Public Company Limited
BK:TITLE
Thailand ฿12.09 Billion
Kitanotatsujin Corporation
PINK:KITAF
USA $1.07 Billion
ZenaTech Inc.
NASDAQ:ZENA
USA $37.34 Million
Avjennings Ltd
AU:AVJ
Australia AU$391.73 Million
A-Jin Industry Co Ltd
KQ:013310
Korea ₩1.15 Trillion

Liability Composition Analysis (1997–2024)

This chart breaks down Transgene SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.54 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -12.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.09 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Transgene SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Transgene SA (1997–2024)

The table below shows the annual total liabilities of Transgene SA from 1997 to 2024.

Year Total Liabilities Change
2024-12-31 $26.97 Million -8.90%
2023-12-31 $29.61 Million +3.53%
2022-12-31 $28.59 Million -17.42%
2021-12-31 $34.63 Million -1.63%
2020-12-31 $35.20 Million -29.28%
2019-12-31 $49.78 Million -30.71%
2018-12-31 $71.84 Million -1.29%
2017-12-31 $72.78 Million -4.79%
2016-12-31 $76.45 Million +2.86%
2015-12-31 $74.32 Million +7.54%
2014-12-31 $69.11 Million -0.16%
2013-12-31 $69.23 Million +13.70%
2012-12-31 $60.89 Million +16.71%
2011-12-31 $52.17 Million +30.20%
2010-12-31 $40.07 Million +33.11%
2009-12-31 $30.10 Million -7.16%
2008-12-31 $32.42 Million +86.58%
2007-12-31 $17.38 Million +27.54%
2006-12-31 $13.63 Million +20.92%
2004-12-31 $11.27 Million -0.27%
2003-12-31 $11.30 Million -3.20%
2002-12-31 $11.67 Million -8.71%
2001-12-31 $12.79 Million -2.76%
2000-12-31 $13.15 Million +15.22%
1999-12-31 $11.41 Million +0.77%
1998-12-31 $11.33 Million +19.61%
1997-12-31 $9.47 Million --